Preventive effects with teriparatide or alendronate on the progression of vertebral collapse
Not Applicable
- Conditions
- Osteoporosis
- Registration Number
- JPRN-UMIN000013014
- Lead Sponsor
- Kitakyushu Osteoporosis Trial Unit
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with vertebral compression fractures which is not clear the time of injury. 2. Patients received teriparatide or denosumab within 6 months prior to the study. 3. Patients with contraindications of teriparatide or alendronate. 4. Patients with severe renal dysfunction, severe liver dysfunction, or severe heart disease. 5. Inappropriate patients to participate the study judged by primary physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method